Prakt. lékáren. 2017; 13(4): 151-155 | DOI: 10.36290/lek.2017.021

Drug induced movement disorders – basics for pharmacologists

Marek Baláž1, Tomáš Kašpárek2
1 I. neurologická klinika LF MU, FN u sv. Anny v Brně
2 Psychiatrická klinika LF MU, FN Brno

Drug induced movement disorders may appear after number of pharmacological treatments. Dopaminergic-treatment relatedchorea in Parkinson’s disease and tardive dyskinesia are the ones most well described.Determination of the type of hyperkinesia is very important for the diagnosis of drug-induced movement disorders, as the treatmentsdiffer across the various clinical phenomena. Treatments are based on tapering of dose or discontinuation of offendingdrug but may include also targeted pharmacotherapy, botulinum toxin or deep brain stimulation.

Keywords: akathisia, dystonia, tardive dyskinesia, drug-induced parkinsonism, neuroleptic malignant syndrome

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Baláž M, Kašpárek T. Drug induced movement disorders – basics for pharmacologists. Praktické lékárenství. 2017;13(4):151-155. doi: 10.36290/lek.2017.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dostál V, Ehler E. Polékové extrapyramidové syndromy. Neurol. Pro Praxi, 2003; 3: 140-143.
    2. Chen JJ. Drug-induced movement disorders. Mental Health Clinician, 2012; 1(7): 67-173. Go to original source...
    3. Bhidayasiri R, Suthida B. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011; 87: 132-141. Go to original source... Go to PubMed...
    4. Haskovec L. L'Akathisie. Rev Neurol 1901; 9: 1107-1109.
    5. Goldberg JF. A case of akathisia after switching from branded to generic high dose olanzapine. J. Clin. Psychiatry 2012; 73(4): 497. Go to original source... Go to PubMed...
    6. Gold R, Lenox RH. Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. J Clin Psychiatry. 1995; 56(10): 476-83.
    7. Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L. Drug-induced movement disorders Expert Opinion on Drug Safety 2015; 14(6): 877-890. Go to original source... Go to PubMed...
    8. Apetauerova D, Schirmer CM, Shils JL, Zani J, Arle JE. Successful bilateral deep brain stimulation of the globus pallidus internus for persistent status dystonicus and generalized chorea: Report of 2 cases. Journal of Neurosurgery, 2010; 113(3): 634-638. Go to original source... Go to PubMed...
    9. Baláž M, Bočková M. Myoklonus. Neurol. pro praxi 2011; 12(1): 22-25.
    10. Brefel-Courbon C, Gardette V, Ory F, Montastruc JL. Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin 2006; 36: 333-336. Go to original source... Go to PubMed...
    11. Fahn S. The Tardive Dyskinesias in Recent Advances in Clinical Neurology, 1984, Vol 4. WB Matthews and GH Glasser (eds.), Edinburgh, Churchill Livingstone, 229-260.
    12. Baldessarini RJ, Cole JO, Davis JM, Simpson G, Tarsy D, Gardos G. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psych, 1980; 137: 1163-1172. Go to original source... Go to PubMed...
    13. Mehta SH, Sethi KD. Drug.induced movement disorders. In: Movement disorders in Neurologic and Systemic Disease. 2014 W. Poewe, J. Jankovic (eds.), Cambridge University Press, 203-220.
    14. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013; 9: 1371-1380. Go to original source... Go to PubMed...
    15. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Mov Disord. 2017; 32: 227-234. Go to original source... Go to PubMed...
    16. Kopal A, Dostál V, Geier P, Ehler E. Neuroleptický maligní syndrom u pacientky s Parkinsonovu nemocí a interkurentní infekcií. Neurol. pro praxi, 2006; 3: 158-159.
    17. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am. 2005; 28(1): 255-274. Go to original source... Go to PubMed...
    18. Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. The Journal of Clinical Psychiatry 2012; 73(11): 1434-1438. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.